Table 2.
Clinical characteristics of propensity-matched cohorts of patients when switching to fingolimod or another iDMT therapy due to failure of earlier iDMT therapy
| Characteristics | Fingolimod cohort (n = 99) | iDMT cohort (n = 99) | p value | ||
|---|---|---|---|---|---|
| Age when switching (years) | |||||
| Mean | 39.5 | 40.6 | |||
| 95 % confidence interval | 37.6–41.3 | 38.6–42.7 | |||
| Standard deviation | 9.3 | 10.2 | |||
| Median | 39 | 40 | 0.4801 | ||
| Gender (n, %) | |||||
| Male | 25 | 25.30 % | 23 | 23.20 % | 0.7401 |
| Female | 74 | 74.70 % | 76 | 76.80 % | |
| Days follow-up after switching (n, %) | |||||
| 180-359 | 11 | 11.10 % | 4 | 4.00 % | |
| 360-719 | 36 | 36.40 % | 9 | 9.10 % | |
| 720+ | 52 | 52.50 % | 86 | 86.90 % | |
| Mean | 833.5 | 1242.3 | |||
| 95 % confidence interval | 757.1–909.9 | 1153.9–1330.8 | |||
| Standard deviation | 383 | 443.4 | |||
| Median | 758 | 1238 | <0.0001 | ||
| Relapses | |||||
| Proportion of patients with a relapse (n, %) | 76 | 76.80 % | 67 | 67.70 % | 0.1533 |
| Relapse in the 90 days prior to index | 33 | 33.30 % | 35 | 35.40 % | 0.7647 |
| Relapse in the 180 days prior to index | 46 | 46.50 % | 47 | 47.50 % | 0.8868 |
| Number of pre-index relapses, 1–360 days prior to index | |||||
| 0 | 38 | 38.40 % | 41 | 41.40 % | |
| 1 | 41 | 41.40 % | 38 | 38.40 % | |
| 2 | 16 | 16.20 % | 13 | 13.10 % | |
| 3+ | 4 | 4.00 % | 7 | 7.10 % | |
| Mean | 0.9 | 0.87 | 0.7158 | ||
| 95 % confidence interval | 0.70–1.10 | 0.68–1.05 | |||
| Standard deviation | 0.98 | 0.93 | |||
| Median | 1 | 1 | |||